Substudy 06C is an open-label phase 1/2 umbrella platform trial evaluating MK-2870 in combination with pembrolizumab (MK-3475) and chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastroesophageal adenocarcinoma (gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and esophageal adenocarcinoma). The objective of the study is to evaluate this combination strategy in the first-line setting. Eligible participants are adults with unresectable or metastatic disease. The trial is conducted using an open-label platform design.
This phase 1/2 clinical trial is studying a new investigational drug called MK-2870 in combination with pembrolizumab and chemotherapy. The treatment is being tested in patients with advanced stomach cancer or cancer at the junction of the esophagus and stomach that cannot be removed by surgery or has spread to other parts of the body. It is used as the first treatment for advanced disease. The aim of the study is to further evaluate this new combination therapy. The study is open-label, meaning that both doctors and participants know which treatment is given.
